Prolocor, a Philadelphia, PA-based healthcare startup developing a precision diagnostic test, raised $1.7M in Bridge funding.
Backers included Green Park & Golf Ventures (GPG Ventures) and the Labcorp Venture Fund.
The company intends to use the funds for ongoing clinical program and commercialization in 2024.
Led by CEO Dr. Peter DiBattiste, and CSO Dr. David Schneider, Prolocor is a healthcare startup developing a precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test). The prognostic tool being developed by the company will help guide treatment decisions, effectively matching the intensity of therapy with the risk of events.
